Cargando…
Novel agents for chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is a heterogeneous group of B-cell neoplasm. CLL is typically sensitive to a variety of cytotoxic agents, but relapse frequently occurs with conventional approaches. The treatment of CLL is evolving rapidly with the introduction of novel drugs, such as bendamustine...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659027/ https://www.ncbi.nlm.nih.gov/pubmed/23680477 http://dx.doi.org/10.1186/1756-8722-6-36 |
| _version_ | 1782270384627777536 |
|---|---|
| author | Wu, Mei Akinleye, Akintunde Zhu, Xiongpeng |
| author_facet | Wu, Mei Akinleye, Akintunde Zhu, Xiongpeng |
| author_sort | Wu, Mei |
| collection | PubMed |
| description | Chronic lymphocytic leukemia (CLL) is a heterogeneous group of B-cell neoplasm. CLL is typically sensitive to a variety of cytotoxic agents, but relapse frequently occurs with conventional approaches. The treatment of CLL is evolving rapidly with the introduction of novel drugs, such as bendamustine, ofatumumab, lenalidomide, ibrutinib, idelalisib, veltuzumab, XmAb5574, navitoclax, dasatinib, alvespimycin, and TRU-016. This review summarizes the most current clinical experiences with these agents in the treatment of CLL. |
| format | Online Article Text |
| id | pubmed-3659027 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-36590272013-05-21 Novel agents for chronic lymphocytic leukemia Wu, Mei Akinleye, Akintunde Zhu, Xiongpeng J Hematol Oncol Review Chronic lymphocytic leukemia (CLL) is a heterogeneous group of B-cell neoplasm. CLL is typically sensitive to a variety of cytotoxic agents, but relapse frequently occurs with conventional approaches. The treatment of CLL is evolving rapidly with the introduction of novel drugs, such as bendamustine, ofatumumab, lenalidomide, ibrutinib, idelalisib, veltuzumab, XmAb5574, navitoclax, dasatinib, alvespimycin, and TRU-016. This review summarizes the most current clinical experiences with these agents in the treatment of CLL. BioMed Central 2013-05-16 /pmc/articles/PMC3659027/ /pubmed/23680477 http://dx.doi.org/10.1186/1756-8722-6-36 Text en Copyright © 2013 Wu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Review Wu, Mei Akinleye, Akintunde Zhu, Xiongpeng Novel agents for chronic lymphocytic leukemia |
| title | Novel agents for chronic lymphocytic leukemia |
| title_full | Novel agents for chronic lymphocytic leukemia |
| title_fullStr | Novel agents for chronic lymphocytic leukemia |
| title_full_unstemmed | Novel agents for chronic lymphocytic leukemia |
| title_short | Novel agents for chronic lymphocytic leukemia |
| title_sort | novel agents for chronic lymphocytic leukemia |
| topic | Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659027/ https://www.ncbi.nlm.nih.gov/pubmed/23680477 http://dx.doi.org/10.1186/1756-8722-6-36 |
| work_keys_str_mv | AT wumei novelagentsforchroniclymphocyticleukemia AT akinleyeakintunde novelagentsforchroniclymphocyticleukemia AT zhuxiongpeng novelagentsforchroniclymphocyticleukemia |